ArticleFrontiers in pharmacology2025
Quantifying structural selection bias in observational cohort data: a ponderation analysis of age - specific incidence rates to inform vaccine safety verification.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Scientific and technological mapping of big data architectures in healthcare.Frontiers in public health · 2026Pooled it
- Enhancing public health surveillance: A statistical validation of potential sampling bias in large retrospective vaccine cohorts.AIMS public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A recent nationwide cohort study reported an unadjusted Hazard Ratio (HR) of 2.714 for Vitiligo incidence following COVID-19 vaccination, indicating a major safety concern. This finding was based on cohorts with an ≈ 11-year age difference, immediately raising critical concerns regarding extreme structural selection and detection bias. Objectives: We hypothesize that this extreme association is an artifact of a fatal methodological flaw, challenging the study's internal validity and subsequent external validity. We aim to quantitatively separate the HR attributable to the structural age imbalance (HR Structural) from the residual HR (HR Residual), which quantifies the uncorrected methodological failure and residual confounding. We further perform a plausible recalculation of risk to demonstrate the complete collapse of the risk signal upon correcting the methodological failure in the baseline cohort. Methods: We performed a direct age-standardization analysis analysis using the age distribution of the scrutinized study's cohorts (Vaccinated, mean age = 56.32 years vs. Non-Vaccinated, mean age = 45.51 years) and applied established national age-specific Vitiligo incidence rates (IR) from external epidemiology. Results: The HR Structural was calculated to be 1.2104. The remaining HR Residual of 2.2423 quantifies the uncorrected methodological failure. The NV cohort's observed incidence rate (0.67/10,000) was found to be nearly 70% lower than the expected rate (2.2146/10,000), providing quantifiable evidence of profound non-comparability. The subsequent recalculation of risk, correcting for this baseline failure, reduces the observed HR of = 2.714 to an HR Corrected of 1.0025, thus completely annulling the signal of risk due to vaccination. Discussion: The HR = 2.714 of the scrutinized study is an unstable statistical artifact. The overwhelming majority of the observed association is a consequence of a fatal design flaw. The HR Corrected of almost 1 confirms that correcting the methodological error eliminates the risk signal, demonstrating a severe lack of internal and external validity of the original study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.